Pharmacokinetics, Pharmacodynamics, and Tolerability of Opicapone in Healthy Chinese and Caucasian Subjects: An Open-Label, Single-Center, Phase 1 Study

被引:1
|
作者
Cong, Duanduan [1 ]
Song, Jie [2 ]
Liu, Yue [1 ]
Tan, Yan [2 ]
Xue, Wei [1 ]
Liu, Xiaohui [1 ]
Qi, Wenyuan [1 ]
Lu, Jun [2 ]
Yuan, Xiaojuan [3 ]
Zhou, Yongchun [3 ]
Hui, Ai-Min [2 ]
Li, Kexin [1 ]
机构
[1] Chinese Acad Med Sci, Clin Trial Ctr, Beijing Hosp, Natl Ctr Gerontol,Inst Geriatr Med,Assessment Cli, 1 Dahua Rd, Beijing 100005, Peoples R China
[2] Shanghai Fosun Pharmaceut Dev Co Ltd, Clin Res Dept, Shanghai 200000, Peoples R China
[3] Wanbang Biopharmaceut Co Ltd, Xuzhou, Jiangsu, Peoples R China
关键词
Clinical trial; COMT inhibitor; Ethnicity; Opicapone; Pharmacodynamics; Pharmacokinetics; Tolerability; CATECHOL-O-METHYLTRANSFERASE; PARKINSONS-DISEASE; MOTOR FLUCTUATIONS; LEVODOPA; INHIBITORS; DISCOVERY; THERAPY; ADJUNCT; LIVER;
D O I
10.1007/s40120-021-00314-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction This study evaluated the pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple doses of opicapone (OPC) in healthy Chinese and Caucasian subjects. Methods In this open-label, single-center, phase 1 study, eligible Chinese subjects received one of three OPC doses (25, 50, or 100 mg), and Caucasian subjects received either 25 or 50 mg of OPC. All subjects were administered a single dose of OPC, whereas subjects in the 50-mg OPC group continued to receive once-daily doses of 50 mg OPC for 10 days. The primary endpoint was to evaluate and compare the plasma concentrations and PK parameters of OPC and its main metabolite, and erythrocyte-soluble catechol-O-methyltransferase (S-COMT) activity in Chinese subjects with that of Caucasian subjects. The secondary endpoint was to evaluate the safety of OPC in Chinese subjects. The estimated results for geometric mean ratios (GMRs) were evaluated with the standard bioequivalence (BE) limits between 80% and 125% to evaluate the ethnic differences. All statistical analyses were performed using SAS version 9.4. Results In total, 70 subjects (45 Chinese, 25 Caucasian) were enrolled; the majority of them were male (85.7%). The plasma exposure of both OPC and BIA 9-1103 increased in an approximately dose-proportional manner in both populations. Maximum S-COMT inhibition ranged from 79% to 95% after a single dose and was about 94% after a 10-day once-daily regimen in both populations. The point estimates of GMRs (Chinese/Caucasian) and 90% CI, except C-max in 25-mg and 50-mg OPC groups, for PK and PD parameters were within 80% to 125%. Furthermore, no new risks or safety concerns associated with OPC were identified, indicating a tolerable safety profile in healthy Chinese subjects. Conclusion Ethnicity had no significant impact on PK and PD parameters after single or multiple doses of OPC, and OPC was safe and tolerable in healthy Chinese subjects.
引用
收藏
页码:283 / 301
页数:19
相关论文
共 50 条
  • [31] The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects
    Small, David S.
    Kothare, Prajakti
    Yuen, Eunice
    Lachno, D. Richard
    Li, Ying G.
    Winters, Kenneth J.
    Farid, Nagy A.
    Ni, Lan
    Jakubowski, Joseph A.
    Salazar, Daniel E.
    Thieu, Vivian T.
    Payne, Christopher D.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (02) : 127 - 135
  • [32] Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single-center, open-label phase I trial
    Deng, Kunhong
    Zou, Yi
    Zou, Chan
    Wang, Hong
    Xiang, Yuxia
    Yang, Xiaoyan
    Yang, Shuang
    Cui, Chang
    Yang, Guoping
    Huang, Jie
    CANCER MEDICINE, 2023, 12 (02): : 1431 - 1440
  • [33] The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy caucasian subjects
    Small, D. S.
    Kothare, P. A.
    Yuen, E. S.
    Lachno, R. D.
    Li, Y. G.
    Winters, K. J.
    Farid, N. A.
    Ni, L.
    Salazar, D. E.
    Payne, C. D.
    AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (8B): : 19C - 19C
  • [34] Pharmacokinetics and bioequivalence of sunitinib and Sutent® in Chinese healthy subjects: an open-label, randomized, crossover study
    Wang, Yanli
    Deng, Qiaohuan
    Gao, Zhenyue
    Liu, Guangwen
    Su, Zhengjie
    Zhao, Yicheng
    Zhang, Lixiu
    Yang, Haimiao
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [35] The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects
    David S. Small
    Prajakti Kothare
    Eunice Yuen
    D. Richard Lachno
    Ying G. Li
    Kenneth J. Winters
    Nagy A. Farid
    Lan Ni
    Joseph A. Jakubowski
    Daniel E. Salazar
    Vivian T. Thieu
    Christopher D. Payne
    European Journal of Clinical Pharmacology, 2010, 66 : 127 - 135
  • [36] Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study
    Alberto Papi
    Andrea F. D. Di Stefano
    Milko Radicioni
    Advances in Therapy, 2021, 38 : 468 - 478
  • [37] Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study
    Papi, Alberto
    Di Stefano, Andrea F. D.
    Radicioni, Milko
    ADVANCES IN THERAPY, 2021, 38 (01) : 468 - 478
  • [38] Pharmacokinetics and Safety of Ezetimibe/Simvastatin Combination TabletAn Open-Label, Single-Dose Study in Healthy Chinese Subjects
    Nan-Nan Chu
    Wei-Li Chen
    Hong-Rong Xu
    Xue-Ning Li
    Clinical Drug Investigation, 2012, 32 : 791 - 798
  • [39] Pharmacokinetics and Safety of Ezetimibe/Simvastatin Combination Tablet An Open-Label, Single-Dose Study in Healthy Chinese Subjects
    Chu, Nan-Nan
    Chen, Wei-Li
    Xu, Hong-Rong
    Li, Xue-Ning
    CLINICAL DRUG INVESTIGATION, 2012, 32 (12) : 791 - 798
  • [40] Pharmacokinetics of Orally Administered Single- and Multiple-Dose Olopatadine in Healthy Chinese Subjects An Open-Label Study
    Chu, Nan-Nan
    Chen, Wei-Li
    Xu, Hong-Rong
    Li, Xue-Ning
    CLINICAL DRUG INVESTIGATION, 2009, 29 (07) : 451 - 457